Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Our specialist services

Adaptive Phase I & II
Adaptive Phase III
TQT Studies
Bridging Studies
Patient Recruitment
Data Management
YOU ARE HERE: HOME > NEWS

Richmond Pharmacology supports ReViral with the development of Sisunatovir

9
September 2020

ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.

View Articles

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

17
August 2020

Richmond Pharmacology early phase drug development update.

View Articles

Dr Jorg Taubel, CEO of Richmond Pharmacology, features on the PM Live website, discussing clincial trials and COVID-19

11
August 2020

Dr Jorg Taubel discusses some of the steps taken at Richmond Pharmacology to ensure clinical trials can continue to operate at a high standard throughout the COVID-19 pandemic.

View Articles

COVID-19 – External Monitoring Guidelines

1
July 2020

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

View Articles

Statement: COVID-19

23
March 2020

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.

View Articles

First transdermal patch to treat schizophrenia hits market

18
March 2020

The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful

View Articles

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Careers at Richmond

We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.

Our Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Events

HFA 2025

17–20 May 2025
Richmond Pharmacology will participate in HFA 2025 in Belgrade from 17–20 May, focusing on heart failure research, clinical trials, and scientific collaboration.
View event
© 2024 Richmond Pharmacology - all rights reserved
Disclaimer
|
Sitemap
|
Privacy Policy
|
Report A Concern
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesRejectAccept